Navigation Links
Cell Therapeutics, Inc. Reports First Quarter Accomplishments and Financial Results
Date:4/26/2011

tment of relapsed/refractory diffuse large B-cell lymphoma ("DLBCL").  The trial, referred to as the PIX-R or PIX 306 trial, will compare a combination of pixantrone plus rituximab to a combination of gemcitabine plus rituximab in patients with relapsed or refractory DLBCL who have received one to three prior lines of therapy.
  • Met with officials of the FDA's OND and presented arguments supporting CTI's belief that the data contained in its NDA 22-481 supports the conclusion that pixantrone is effective for its planned use. CTI expects a decision on its appeal during the second quarter of 2011.
  • Received the day 120 list of questions from the EMA relating to our MAA for pixantrone in Europe.

  • For the quarter ended March 31, 2011, total operating expenses decreased to $20.1 million compared to $25.8 million for the same period in 2010.  Research and development expenses increased to $11.5 million in the quarter ended March 31, 2011 compared to $7.4 million for the same period in 2010 due to a one-time upfront payment of $5.0 million related to the licensing of tosedostat from Chroma in 2011. Selling, general and administrative expenses decreased to $8.6 million in the quarter ended March 31, 2011 compared to $18.4 million for the same period in 2010 primarily related to a decrease in non-cash equity based compensation. Net loss attributable to common shareholders was $51.0 million ($0.06 per share) for the quarter ended March 31, 2011 compared to a net loss attributable to common shareholders of $44.2 million ($0.07 per share) for the same period in 2010. The increase in net loss attributable to common shareholders is mainly due to an increase in non-cash deemed dividends on preferred stock related to financing activities.

    CTI had approximately $43.8 million in cash and cash equivalents as of March 31, 2011.Conference Call InformationOn Wednesday, April 27, 2011, at 8:30 a.m. Eastern/2:30 p.m. Central European/5:30 a.m.
    '/>"/>

    SOURCE Cell Therapeutics, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related medicine technology :

    1. Vista Partners Updates Coverage on Opexa Therapeutics, Inc.; Maintains Target Price of $6.50
    2. Orexigen® Therapeutics, Inc. Announces Upcoming Departure of Chief Financial Officer
    3. Cell Therapeutics, Inc. (CTI) to Report Fourth Quarter and Year-End 2010 Financial Results on February 16
    4. Alpha-1 Foundation Awards Two Research Grants with Support from Talecris Biotherapeutics, Inc.
    5. Cell Therapeutics, Inc. (CTI) Submits European Marketing Authorization Application for Pixuvri®
    6. Veteran Pharmaceutical Executives Form New American Therapeutics, Inc.
    7. BioMolecular Therapeutics, a New Global Player in RNAi Therapeutics, Launches Company and Adds Key Advisors
    8. Precision Therapeutics, Inc. Named to Pittsburgh Business Times 2010 Top 100
    9. BioMarin Acquires ZyStor Therapeutics, Inc.
    10. Nonconformity of NOV002 Used in Phase 3 NSCLC Trial Sponsored by Novelos Therapeutics, Inc to NOV002 (Glutoxim(R)), Used in Phase 1/2 NSCLC and all Previous Trials
    11. Reportlinker Adds The Future of Ophthalmology Therapeutics, Analysis and Market Forecasts to 2016 - Strategies to Counter Generic Erosion in Key Markets
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/31/2015)... MONROVIA, Calif. , July 31, 2015  Xencor, ... developing engineered monoclonal antibodies for the treatment of autoimmune ... the appointment of Yujiro S. Hata to ... of experience in business and corporate development is a ... , Ph.D., president and chief executive officer of Xencor. ...
    (Date:7/31/2015)... , July 31, 2015 ... for video, data and cloud computing operators has ... leading pharma giant for Internet of Things (IoT) ... applications offered on subscription model.      ... giant is striving for business innovations to make ...
    (Date:7/30/2015)... -- Mettler-Toledo International Inc. (NYSE: MTD ) today ... the highlights: , Sales in local currency ... year. Reported sales decreased 4% as currency reduced sales ... earnings per diluted share as reported (EPS) were $2.73, ... was $2.80 , an increase of 9% over ...
    Breaking Medicine Technology:Xencor Appoints Yujiro S. Hata to Board of Directors 2Xencor Appoints Yujiro S. Hata to Board of Directors 3Magnaquest Signs a POC With a Leading Pharma Giant in Europe to Manage Subscription Management and Billing for Internet of Things (IoT) 2Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 2Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 3Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 4Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 5Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 6Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 7Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 8Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 9Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 10Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 11Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 12Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 13Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 14
    ... at the,World Congress of Cardiology (WCC), the press ... by John Camm,Professor of Clinical Cardiology, St George,s ... announced ATHENA clinical trial,results, as the way forward ... common form of cardiac arrhythmia., To view ...
    ... of 2008 --,-- Presentation at the Seventh Annual JMP Securities ... update scheduled during Ardea,s ... --, SAN DIEGO, May 20 Ardea Biosciences, Inc.,(Nasdaq: ... the Company,s,lead mitogen-activated ERK kinase (MEK) inhibitor, RDEA119, demonstrating,potent activity ...
    Cached Medicine Technology:ATHENA Clinical Results for Dronedarone (Multaq(R)) Highlighted at the World Cardiology Congress 2ATHENA Clinical Results for Dronedarone (Multaq(R)) Highlighted at the World Cardiology Congress 3ATHENA Clinical Results for Dronedarone (Multaq(R)) Highlighted at the World Cardiology Congress 4ATHENA Clinical Results for Dronedarone (Multaq(R)) Highlighted at the World Cardiology Congress 5ATHENA Clinical Results for Dronedarone (Multaq(R)) Highlighted at the World Cardiology Congress 6Ardea Biosciences Presents Preclinical Data on RDEA119 Demonstrating Favorable Anti-Inflammatory Profile for Potential Use in Ulcerative Colitis 2Ardea Biosciences Presents Preclinical Data on RDEA119 Demonstrating Favorable Anti-Inflammatory Profile for Potential Use in Ulcerative Colitis 3Ardea Biosciences Presents Preclinical Data on RDEA119 Demonstrating Favorable Anti-Inflammatory Profile for Potential Use in Ulcerative Colitis 4
    (Date:8/1/2015)... , ... August 01, 2015 , ... The condition where ... both men and women often causing pain and discomfort. Those who spend a lot ... problem, and Northeast Houston Vein Center is doing what it can to create awareness ...
    (Date:8/1/2015)... ... August 01, 2015 , ... On Tuesday, July 28th, Symantec ... are thought to have been behind the attack on Anthem Inc. which resulted in ... day exploits, watering hole attacks and spear phishing campaigns. , For Joe ...
    (Date:7/31/2015)... ... 31, 2015 , ... That’s right, the STASH awards have ... The Significant Technological Achievements in Secretive Horticulture (or STASH) Awards, featured in High ... that have stood the test of time. These include lighting products, organic and ...
    (Date:7/31/2015)... Chicago, IL (PRWEB) , ... July 31, 2015 , ... ... which is currently going on in Chicago at Grant Park. The festival ... every corner of North America to Chicago for the annual Lollapalooza. This unique ...
    (Date:7/31/2015)... ... July 31, 2015 , ... Sculpted Contours Luxury Medical Aesthetics announces the arrival ... Zeltiq Aesthetics released this new applicator in the United States as an upgrade to ... thighs. The original applicator required a 2 hour treatment time. The new ...
    Breaking Medicine News(10 mins):Health News:Northeast Houston Vein Center Warns Men about Varicose Veins 2Health News:Northeast Houston Vein Center Warns Men about Varicose Veins 3Health News:Frenemy at the Gates - Hackers Excel at Leveraging Trust 2Health News:Frenemy at the Gates - Hackers Excel at Leveraging Trust 3Health News:Frenemy at the Gates - Hackers Excel at Leveraging Trust 4Health News:The High Times S.T.A.S.H. Awards Are in, Guess Who Took Home the Prize for “Best Grow System” 2Health News:Cheap 2015 Lollapalooza Tickets: Ticket Down Slashes Ticket Prices on Lollapalooza Tickets at Grant Park in Chicago for Saturday, August 1st and Sunday, August 2nd 2Health News:Cooler Coolsculpting in Atlanta: Treatments Now Twice As Fast 2Health News:Cooler Coolsculpting in Atlanta: Treatments Now Twice As Fast 3
    ... , Nurtur Receives ... Nov. 23 The Population Health Impact Institute (PHII), a ... of Directors has approved the Healthcare Transparency Accreditation Program, v ... life, health, and wellness company based in Farmington, CT is ...
    ... than most friends, relatives or even healthcare professionals realise, according ... issue of the UK-based Journal of Advanced Nursing . ... had undergone surgery in the last year, together with 105 ... years at the Vanderbilt Transplant Center in Tennessee, USA. They ...
    ... ... Compliance Requirements and Automate Billing, Claims, Enrollment and Eligibility, , ... (PRWEB) November 23, 2009 ... announced today the launch of new products within its healthcare integration suite, designed ...
    ... both increased risk eightfold , MONDAY, Nov. 23 (HealthDay ... who were exposed to lead have more than double ... other children, new research shows. , And with exposure ... ADHD soared. Children whose mothers smoked during pregnancy and ...
    ... , SANTA CLARA, Calif., Nov. 23 NewCardio, Inc., (OTC ... CEO, Dr. Branislav Vajdic, and CFO, Richard Brounstein, will present at ... 4:30 PM PST at the Luxe Sunset Hotel in Los Angeles. ... December 2nd and Thursday, December 3rd. Please contact Brett Aimee ...
    ... ... as Best New Technology Provider for its QlikView Business Intelligence Software , ... Radnor, PA ... company, today announced that it was recognized with the Healthcare IT Innovation™ Award ...
    Cached Medicine News:Health News:Population Health Impact Institute Launches Healthcare Transparency Accreditation Program(TM) 2Health News:Population Health Impact Institute Launches Healthcare Transparency Accreditation Program(TM) 3Health News:Drug side effects a key factor in reduced quality of life for kidney transplant patients 2Health News:Drug side effects a key factor in reduced quality of life for kidney transplant patients 3Health News:BridgeGate Launches New Healthcare Integration and Interoperability Products 2Health News:BridgeGate Launches New Healthcare Integration and Interoperability Products 3Health News:BridgeGate Launches New Healthcare Integration and Interoperability Products 4Health News:Smoking During Pregnancy, Lead Exposure Raise ADHD Risk in Kids 2Health News:Smoking During Pregnancy, Lead Exposure Raise ADHD Risk in Kids 3Health News:NewCardio, Inc. to Present at 2nd Annual LD MICRO Conference 2Health News:NewCardio, Inc. to Present at 2nd Annual LD MICRO Conference 3Health News:QlikTech Wins Healthcare IT Innovation™ Award 2Health News:QlikTech Wins Healthcare IT Innovation™ Award 3Health News:QlikTech Wins Healthcare IT Innovation™ Award 4
    ... Left Ventricular Assist System (LVAS), manufactured by ... used as a destination therapy for patients ... heart failure, for which heart transplantation is ... is not intended as a bridge to ...
    ... The TandemHeart PTVA ( Percutaneous ... unique proprietary solution for the hemodynamic needs ... Cardiologists and Cardiac Surgeons. These specialists ... provide some coronary artery perfusion, but the ...
    The MicroMed DeBakey VAD is a miniaturized heart pump designed to provide increased blood flow (up to 10L/min) from the left ventricle of the heart throughout the body for patients in end stage heart...
    Datascope presents a unique new product for post-hemostasis puncture site management. Safeguard is the first product ever to combine a built-in inflatable bulb and a sterile dressing- providing adjus...
    Medicine Products: